Sanofi (SNYNF)
| Market Cap | 117.46B |
| Revenue (ttm) | 53.89B |
| Net Income (ttm) | 10.69B |
| Shares Out | n/a |
| EPS (ttm) | 8.67 |
| PE Ratio | 10.99 |
| Forward PE | 10.07 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,600 |
| Average Volume | 23,944 |
| Open | 94.12 |
| Previous Close | 95.88 |
| Day's Range | 94.12 - 95.91 |
| 52-Week Range | 90.05 - 122.03 |
| Beta | 0.37 |
| RSI | 49.98 |
| Earnings Date | Jan 29, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsNews
Sanofi a Top Ranked SAFE Dividend Stock With 4.6% Yield (SNY)
Sanofi (Symbol: SNY) has been named to the Dividend Channel ''International S.A.F.E. 10'' list, signifying an international stock with above-average ''DividendRank'' statistics including a strong 4.6%...
Trump Secures Drug Price Cuts From 9 Major Pharma Firms Including Bristol Myers, Gilead, Merck In Medicaid Deal
President Donald Trump and nine major pharmaceutical companies announced agreements to lower the cost of medications for cash payers and the government’s Medicaid program on Friday, bringing U.S. cost...
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients pay
The companies, including Bristol-Myers Squibb, GSK and Merck, would avoid potential U.S. tariffs in return.
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
Officials pledge ‘massive savings’ as companies agree to offer drugs at prices equal to those in other wealthy nations Donald Trump and nine major pharmaceutical companies on Friday announced deals th...
Nine of the largest pharma companies ink deals with Trump to lower drug prices
Several of the largest U.S. and European-based drugmakers inked deals with President Donald Trump to voluntarily sell their medications for less, as his administration pushes to link the nation's drug...
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump's four requests, establishing a framework for lower prices ...
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
Sanofi Receives EMA Orphan Designation For Efdoralprin Alfa
(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) announced that the European Medicines Agency (EMA) has granted orphan designation to efdoralprin alfa (SAR447537), formerly known as INBRX-101.
Press Release: Sanofi's efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
Sanofi's efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema Additional orphan designation reinforces Sanofi's commitment to developing treatments ...
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
Sanofi (SAN) Secures Exclusive Rights to Alzheimer's Therapy ADEL-Y01
Sanofi (SAN) Secures Exclusive Rights to Alzheimer's Therapy ADEL-Y01
Sanofi in up to $1B deal with South Korean biotech for Alzheimer's candidate
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and sell the biotech company's experimental Alzheimer's disease treat...
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ: SNY). The new agreement is built on the existing relationship between the two compani...
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ: SNY). The new agreement is built on the existing relationship between the two companie...
Sanofi (SNY) Enters $1.7B Deal with Dren Bio for Antibody Therapies
Sanofi (SNY) Enters $1.7B Deal with Dren Bio for Antibody Therapies
Sanofi in deal worth up to $1.7B with Dren Bio for autoimmune disease treatments
Sanofi partners with Dren Bio on multispecific antibody therapies in a deal worth up to $1.7B. Read more here.
Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion
Dren Bio, a private biotech company, said on Monday it has entered into a strategic collaboration with Sanofi to develop therapies for autoimmune diseases in a deal worth up to $1.7 billion.
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy.
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks
Sanofi said its Phase 3 PERSEUS ... Full story available on Benzinga.com
Sanofi (SNY) Phase 3 Study Results Impact Regulatory Plans
Sanofi (SNY) Phase 3 Study Results Impact Regulatory Plans
Sanofi (SNY) Expects Extended FDA Review for Tolebrutinib in MS Treatment
Sanofi (SNY) Expects Extended FDA Review for Tolebrutinib in MS Treatment